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Abstract
Background: The aim of the present study was to examine if differences in the endocannabinoid (ECB) system might be
linked to strain specific variations in reward-related behavior in Fischer344 (Fischer) and Wistar rats.
Methodology/Principal Findings: Two rat strains, the Fischer and the Wistar strain, were tested for different aspects of
reward sensitivity for a palatable food reward (sweetened condensed milk, SCM) in a limited-access intake test, a
progressive ratio (PR) schedule and the pleasure-attenuated startle (PAS) paradigm. Additionally, basic differences in the
ECB system and cannabinoid pharmacology were examined in both rat strains. Fischer rats were found to express lower
reward sensitivity towards SCM compared to Wistar rats. These differences were observed for consummatory, motivational
and hedonic aspects of the palatable food reward. Western blot analysis for the CB1 receptor and the ECB degrading
enzyme fatty acid amide hydrolase (FAAH) revealed a lower expression of both proteins in the hippocampus (HPC) of
Fischer rats compared to the Wistar strain. Furthermore, increased cannabinoid-stimulated extracellular-regulated kinase
(ERK) phosphorylation was detected in Wistar rats compared to the Fischer strain, indicating alterations in ECB signaling.
These findings were further supported by the pharmacological results, where Fischer rats were found to be less sensitive
towards the effects of the CB1 receptor antagonist/inverse agonist SR141716 and the cannabinoid agonist WIN 55,212-2.
Conclusions/Significance: Our present findings indicate differences in the expression of the CB1 receptor and FAAH, as well
as the activation of ECB signaling pathways between Fischer and Wistar rats. These basic differences in the ECB system
might contribute to the pronounced differences observed in reward sensitivity between both rat strains.
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Introduction
Cross-strain comparisons have provided a productive approach
to understanding behavioral traits and their underlying neurobi-
ological substrates in rodents. Already in the 1920s it had been
discovered that rodent strains differ in their behavior [1] and since
then many studies have attempted to correlate behavioral
differences with genetic and neurobiological variables [2]. In
particular for emotional behavior it is already well established that
anxiety- and stress-responsiveness in rodents are highly influenced
by the background strain which has been shown in a variety of
different studies [3–7]. Notably, the role of strain differences in the
context of reward-related behaviors is less well studied, especially
for natural rewards. Although various studies indicate pronounced
rat strain differences in the behavioral and molecular response to
drugs of abuse, such as opioids, psychostimulants or ethanol [8–
13], only little is known about similar strain differences on natural
rewards, such as palatable food. Rat strain differences have been
reported for opioid-induced feeding behavior, with Lewis rats
showing a higher feeding responses to morphine than Fischer344
(Fischer) rats [14]. Kearns et al. [15] found that Lewis rats acquire
autoshaping procedures in an operant task for food more rapidly
and also perform at a higher response rate than Fischer rats.
One important neurotransmitter system that is strongly
implicated in the modulation of reward processing for drug and
non-drug rewards is the endocannabinoid (ECB) system [16–19].
However, few studies have investigated if alterations in this
important modulatory system might be involved in strain specific
behavioral variances. One interesting study demonstrated that
Lewis rats are less sensitive to the behavioral, physiological and
neural effects of cannabinoids than Wistar rats, showing mainly
differences in c-fos expression, which were paralleled by
behavioral findings [20]. Additionally, a cannabinoid receptor
agonist was found to induce a stronger effect on anxiety-related
behaviors in the Wistar strain compared to Lewis rats [21].
Further studies were mostly restricted to the rewarding or euphoric
effects of cannabinoids in different rat strains. It has been
demonstrated that Fischer rats show a lower responsiveness
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no towards the effects of D
9-tetrahydrocannabinol (THC) on intracra-
nial self stimulation [22,23]. Furthermore, strain differences have
also been reported on the acquisition and stable performance of
cannabinoid self-administration behavior [24]. These findings on
strain differences in reward-related behaviors upon cannabinoid
treatment are consistent with other studies demonstrating a high
variety of general sensitivity towards drugs of abuse among different
rat strains [8,10,13,25]. Therefore, it is not unlikely that basic
genetic differences in the ECB system might be involved in strain
specific differences in reward perception and sensitivity.
The aim of the present study was to examine basic differences in
reward-related behavior towards a palatable food reward in two
different rat strains. Additionally, differences in ECB signaling and
cannabinoid pharmacology were also investigated. For this study
we chose the outbred Wistar-Han (Wistar) strain and the inbred
Fischer strain, since both strains are well known to differ highly in
their emotional responsiveness [26,27], but have not been
compared so far in the context of reward-related behavior. All
animals were tested for reward sensitivity for a palatable food
reward (limited free sweetened condensed milk (SCM) consump-
tion, progressive ratio (PR) performance and in the pleasure
attenuated startle (PAS) paradigm) and for their behavioral
response towards the CB1 receptor antagonist/inverse agonist
SR141716 (SR) and the cannabinoid agonist WIN 55,212-2
(WIN). Additionally, protein levels of the CB1 receptor and the
principal anandamide (AEA) degrading enzyme fatty acide amide
hydrolase (FAAH) as well as cannabinoid-induced stimulation of
extracellular signal-regulated kinase-1 and -2 (ERK1/2), a
mitogen-activated protein kinase, were examined by Western Blot
analysis in different brain regions involved in reward processing.
Materials and Methods
Ethics Statement
All experiments were done in accordance with the NIH ethical
guidelines for the care and use of laboratory animals for
experiments, and were approved by the Regierungspra ¨sidium
Karlsruhe (Referat 35, Karlsruhe, Germany, 35-9185.81/G-
56/07).
Subjects
A total of 93 animals were used for the present study. Male adult
Wistar Han
TM (Wistar) and Fischer344/NHsd (Fischer) rats were
purchased from Harlan Winkelmann GmbH (Borchen, Germany).
Animals were housed in the same room in Makrolon
TM cages
(Eurostandard type IV) in groups of 6 on a 12 h light-dark
schedule (lights on 8:00–20:00). During all experiments animals
had free access to tap water and standard lab food, except for the
PAS experiment, where animals were maintained on approxi-
mately 95% of their free-feeding bodyweight during testing and
training. Before testing started, animals were allowed to recover
from transportation and were habituated to the new environment
and the experimenter for at least 7 days after arrival.
Drugs
The CB1 receptor agonist WIN 55,212-2 (WIN) (Sigma-Aldrich,
Munich, Germany) was freshly dissolved in Tween80 (Sigma-
Aldrich, Munich, Germany) and diluted in Saline (0.9%) (Fresenius
Kabi, Bad Homburg, Germany). For stimulation of phospho-ERK
(pERK), vehicle (Tween80 and Saline) or WIN (2 mg/kg), were
administered intraperitoneally 1 hour prior to decapitation with an
injection volume of 1 ml/kg. For open field testing, vehicle
(Tween80 and Saline) or WIN (2 mg/kg) were injected 10 min
prior to behavioral testing. The CB1 receptor antagonist/inverse
agonist SR141716 (SR; Rimonabant) (generously provided by
NIMH) was dissolved in ethanol and Tween80 and diluted with
saline. Three different concentrations were used for pharmacolog-
ical experiments: 0.3, 0.6 and 1.2 mg/kg. SR was injected 30 min
prior to testing with an injection volume of 1 ml/kg.
Experimental design
For the present study three different cohorts of Fischer and
Wistar rats were used. The first group (Fischer and Wistar: n=12)
was used for testing of reward-related behaviors. All animals were
tested for SCM intake, followed by performance in a PR task and
the PAS paradigm. Animals were left undisturbed for 1 week
between the different behavioral tasks. After cessation of
behavioral testing some of these animals (Fischer and Wistar:
n=8) were further used to examine the effects of WIN in an open
field. The second cohort of animals (Fischer: n=11, Wistar:
n=10) was used for pharmacological testing where the effects of
the CB1 receptor antagonist/inverse agonist SR on SCM intake
were investigated. Finally, a third group of naive rats was used for
molecular analysis (CB1: Fischer and Wistar: n=6, FAAH:
Fischer and Wistar: n=6, pERK: Fischer and Wistar: n=12).
For pERK stimulation, 6 rats of each strain received the vehicle
injection and the rest were treated with 2 mg/kg WIN.
Since it is well known that Fischer rats are more anxious than
Wistar rats [4,26,27], all animals were habituated extensively to
experimental conditions and procedures in order to exclude
possible novelty or stress effects.
Behavioral Testing
Sweetened Condensed Milk (SCM) Intake. SCM (Leche
Condensada, La Lechera from Nestle Barcelona, Spain) was
freshly mixed 1:3 with water on the day of use. All rats were
habituated once in their homecage for 24 h to the SCM, 72 h
prior to testing as previously described [28]. The test was
conducted in single cages (Makrolon
TM, Eurostandard type III)
and in order to avoid novelty-induced hypophagia animals were
additionally habituated for two consecutive days to the single cages
and SCM presentation in these single cages. On the test day, the
body weight was measured and animals were placed in the single
test cages. After an inital cage habituation time of 5 minutes, they
received free access to a bottle of SCM for 15 minutes. SCM
intake was then calculated as g intake per kg body weight (BW).
Progressive Ratio (PR) testing for SCM. PR test and
training were conducted in an operant chamber (30.5 cm6
24.1 cm621.0 cm from Med Associates Inc., St. Albans, USA),
which was controlled by the computer program MED-PCIV (Med
Associates Inc.) as previously described [29]. During the first three
days rats were habituated for 20 min daily to the operant chamber
with free access to SCM (shaping). After shaping, rats were trained
for lever-pressing in sessions of 30 minutes. Pressing the lever was
paired with access to 90 ml SCM (reward) and a light signal.
Training was performed under continuous reinforcement (CRF)
until a stable baseline was reached (at least 60 lever presses per
session). Rats not accomplishing this criterion at least 2 days prior
to the PR test were excluded. After lever-response training was
completed, one PR session (for 30 minutes) was conducted on the
subsequent day. In that test the number of lever presses required to
obtain a reward increased sequentially according to a PR2
progression: 1, 2, 4, 6, 8, 10, .., . During PR testing three
behavioral measures were recorded. First we recorded the total
number of lever presses and also the highest completed PR
sequence during the 30 minute test session. Finally, the inactivity
ratio, which is defined as the final completed sequence before the
animals ceased responding for more than 2 minutes, was used to
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This break point is considered an operational measure for a shift in
motivation, where the rewarding value is lower than the effort the
animal is willing to invest to obtain this reward (Schneider et al.
2010).
Pleasure-attenuated startle (PAS). Startle testing occurred
in a startle chamber (SR-LAB; San Diego Instruments, San Diego,
USA) that has been previously described in detail [28,29]. A white
noise pulse was used as the startle stimulus, with duration of 40 ms
and an intensity of 100 dB sound pressure level (SPL) in Wistar
rats and 115 dB SPL in Fischer rats. Preliminary experiments
indicated Fischer rats showing a much lower startle reaction than
Wistar rats, or even no response at all, when tested with the same
startle intensity. We therefore performed a series of initial
experiments in order to detect the startle stimulus intensity at
which Fischer rats show a robust acoustic startle response (ASR)
amplitude (data not shown), which was found to be 115 dB. An
acclimatization time of 5 min, during which the rats received no
stimulus except for the background noise (60 dB), was followed by
the presentation of 5 initial startle stimuli. The test protocol
consisted of 30 startle pulses with an inter-trial interval
randomized between 10 and 20 s. Animals were tested twice for
their ASR in the presence of an odor cue (orange, essential oils,
Primavera Life, Sulzberg, Germany), once prior (=ASR baseline;
ASR1) and again 24 hours after 5 days of odor-reward association
training (ASR2). The odor (30 ml) was provided in a petri dish that
was placed in the box during habituation. PAS was calculated
as mean percent decrease over baseline ASR amplitude
[1002(1006mean ASR2 amplitude/mean ASR1 (baseline)
amplitude)], as previously described. Reward association training
lasted 5 days. During training, lasting 90 min in total, rats were
placed in single cages (Eurostandard type III) and experienced 3
odor-reward presentations at random time points. The odor
(orange, 15 ml) was supplied in a small Petri dish containing a piece
of filter paper that was placed in the middle of the wire lid, 2 cm
beneath the aperture of the SCM drinking bottle.
Pharmacology
Effects of WIN on locomotor activity. In order to assess
basic differences in cannabinoid pharmacology between the two
rat strains, we tested the effects of a high dose of WIN (2 mg/kg)
on locomotor activity in an open field. The open field consisted of
four equal areas (51 cm651 cm650 cm) made of dark PVC.
Distance traveled [cm] was digitally recorded in the open field
apparatus for 30 minutes. The test was started by placing the rats
in the center of the box. For the analysis of locomotor activity the
observation program Viewer
2 (Biobserve GmbH, Bonn, Germany)
was used.
Effects of SR on SCM intake. The effects of the CB1
receptor antagonist/inverse agonist SR were tested with a within-
subject design. We have shown before that SCM intake in adult
rats can be measured repeatedly without any habituation effect
[30]. Therefore, animals were tested four times in the limited
access SCM intake paradigm (every 10
th day) and received on
each day of testing an injection of either vehicle or SR (0.3, 0.6 or
1.2 mg/kg) which was randomized according to a latin square.
SCM intake was then calculated as g intake per kg BW and
additionally the percentage reduction of SCM intake after SR
injections was calculated for each animal.
Molecular Analysis
Rat Brain Preparation and Dissection. Rats were deeply
anesthetized with a mixture of air and carbon dioxide (CO2) and
sacrificed by decapitation. Brains were removed quickly and the
following brain regions were dissected: medial prefrontal cortex
(mPFC), striatum, nucleus accumbens (NAC) and hippocampus
(HPC). Dissected brain tissues were homogenized in 1 ml lysis
buffer (10 mM TrisHCl, 2 mM EDTA, pH 8.0) containing
protease inhibitors (Roche Diagnostics, Penzberg, Germany) on
crushed ice with a glass homogenizer.
Western Blot Analysis of FAAH and CB1 Receptor. The
protein content was measured by the Bradford Protein Assay
(BioRad Laboratories GmbH, Munich, Germany) using bovine
serum albumin (Sigma-Aldrich, Munich, Germany) as standard,
and amounts equivalent to 25 mg of protein of the brain region
were electrophoresed in NuPAGEH Novex Bis-Tris Mini Gel 4–
12% gel (Invitrogen, Darmstadt, Germany) after mixing with 4X
Laemmli’s Sample Buffer and heating up to 95uC for 5 minutes.
Rainbow colored molecular weight marker (GE Healthcare,
Munich, Germany) was included on each gel.
The electrophoresis was carried out at 200 V at room
temperature and proteins were then blotted onto PVDF
membranes (BioRad Laboratories GmbH, Munich, Germany) in
tris/glycine/ethanol transfer buffer at 400 mA for 90 minutes.
The membranes were then incubated with a rabbit polyclonal
antibody against FAAH (amino acids 561–579, C-termi-
nal)(1:1000, Enzo Life Sciences AG, formerly ALEXIS corpora-
tion, Lausen, Switzerland; Cat. No. ALX-210-418) at 4uC over
night in 5% non-fat dry milk solution, followed by HRP
(horseradish-peroxidase)-linked anti-rabbit (1:2000 Cayman
Chemical, Ann Arbor, USA) for 1 hour at room temperature in
2.5% nonfat dry milk solution and developed by chemilumines-
cence (ECL, GE Healthcare, Munich, Germany). Same blots were
washed in water and tris-buffered saline and incubated with
monocolonal anti-ß-Actin (1:2000 New England Biolabs GmbH,
Frankfurt, Germany), followed by HRP-linked anti-rabbit and
visualization by ECL. A similar procedure was used for the
analysis of CB1 receptor levels in brain samples, using the
polyclonal anti-CB1 receptor antibody (against amino acids 1–14
of the CB1 Receptor; N-terminal)(1:1000, Cayman Chemical,
Ann Arbor, USA; Cat. No. 101500). Specificity controls for CB1
receptor detection were performed through preincubation of anti-
CB1 rabbit antibodies with the corresponding specific blocking
peptide (Cayman Chemical, Ann Arbor, USA; antibody/peptide,
1/5).
Western Blot Analysis of extracellular-regulated kinase
(ERK)1/2. 25 mg protein was separated using electrophoresis
and blotted onto PVDF membrane as described for CB1 and
FAAH. The blots were incubated with anti-phospho-p44/42
MAPK (pERK1/2) (1:1000, New England Biolabs GmbH,
Frankfurt, Germany) at 4uC over night in 5% non-fat dry milk
solution, followed by HRP-linked anti-rabbit and developed by
chemiluminescence. Membranes were then incubated with anti-
p44/42 MAPK (ERK1/2) (1:2000, New England Biolabs GmbH,
Frankfurt, Germany) at 4uC over night and HRP-linked anti-
rabbit and developed as described above.
Quantification of Western Blots. For Western Blot analysis
proteins were quantified using a densitometer. The band density
was determined by computer program MCID Core (GE Healthcare
Niagara Inc., St. Catharines, Ontario, Canada). CB1 receptor and
FAAH levels were plotted as quantitative densitometry analysis of
signals corrected on the basis of ß-Actin content. The value of
active pERK1/2 was normalized to the amount of total ERK1/2
in the same sample. Values were expressed as arbitrary units.
Statistical Analysis
Differences between the Wistar and Fischer strains were
analyzed by two-way ANOVA (pERK stimulation), two-way
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distance traveled after WIN injection), one-way repeated measure
ANOVA (SR administration) or by Student’s t-tests (behavioral
tests and Western blots for FAAH and CB1). For post-hoc testing
the Student-Newman-Keuls test was used. During PR testing, one
Wistar and one Fischer rat did not reach the lever press criterion
during training and had to be excluded from PR testing.
All data are expressed as means 6 SEM. The overall level of
statistical significance was defined as p,0.05, a significance level
of p,0.1 was considered a statistical trend.
Results
Behavioral Testing
Limited SCM intake. Differences between the two rat
strains were detected for SCM intake (Figure 1). Wistar rats
consumed significantly more SCM during the 15 min testing
period than animals from the Fischer strain (p=0.002) (Fischer:
n=12, Wistar n=12).
PR testing. Significant differences between animals from the
Fischer and the Wistar strain were observed in PR testing
(Figure 2). The number of total lever presses (p=0.04) and the
highest completed ratio (p=0.04) were significantly lower in
Fischer rats compared to the Wistar strain. However, no
differences between the two rat strains were detected for the
inactivity ratio (‘break point’) (p.0.05) (Fischer: n=11, Wistar
n=11).
PAS. The PAS response was found to be significantly lower in
rats from the Fischer strain compared with Wistar rats (p=0.03),
indicating the conditioned odor-cue induced a lower percentage
reduction in ASR magnitude in Fischer than Wistar rats (Fischer:
n=12, Wistar n=12) (Figure 3).
Pharmacology
WIN effects on locomotor activity. Statistical analysis for
the effects of WIN on locomotory activity revealed a sigificant
interaction effect for the factors treatment and strain (F1,14=10.9,
p,0.05). Post-hoc analysis indicated no significant differences
between Wistar and Fischer rats in general locomotor activity
(p.0.05). However, the two strains differed significantly in their
behavioral response to WIN. The acute injection of WIN
significantly reduced locomotor activity in Wistar (p,0.001), but
not in Fischer rats (p.0.05) (Figure 4) (Fischer: n=8, Wistar
n=8).
Effects of SR on SCM intake. Treatment with the CB1
receptor antagonist/inverse agonist SR reduced SCM intake dose-
dependently in both Wistar (F3,27=11.2, p,0.05) and Fischer rats
(F3,30=5.3, p,0.05) (Figure 5). Post-hoc analysis revealed that all
three doses of SR decreased SCM intake in Wistar rats compared
to vehicle treatment (SR 0.3: p=0.044, SR 0.6: p=0.002, SR 1.2:
p,0.001). Furthermore, the highest dose SR differed also
significantly from the 0.3 mg/kg concentration (p=0.005)
(Figure 5 A).
In the Fischer strain only the two highest concentrations of SR
significantly reduced SCM intake compared to vehicle injections
(SR 0.6: p=0.041, SR 1.2: p=0.006), whereas no effect was found
for the lowest SR dose (p.0.05) (Figure 5 B).
Similar results could be detected for the percentage reduction in
SCM intake. Here an overall strain effect was found (F1,38=8.1,
p,0.05) for the inhibition of SCM consumption by SR between
Fischer rats and the Wistar strain (Figure 5 C).
Molecular Analysis
Protein levels of CB1 and FAAH. CB1 receptor protein
levels were significantly lower in the HPC of Fischer rats
compared to animals of the Wistar strain (t11=3.7; p=0.004)
(Figure 6 A). No differences between the two rat strains were
detected in the mPFC (t11=21.2; p.0.05), striatum (t11=20.6;
p.0.05) and NAC (t11=0.2; p.0.05) (data not shown; Fischer:
n=6, Wistar n=6).
The same brain regions as for CB1 receptor analysis were used
for FAAH western blotting (Figure 6 B). No strain differences were
detected in the striatum (t11=0.02; p.0.05) and NAC (t11=20.1;
p.0.05) (data not shown). However, a significantly lower FAAH
expression was found in the HPC of Fischer rats compared to the
Wistar strain (t11=3.3; p=0.008) (Figure 5 B) and a trend
(t11=2.1; p=0.06) for reduced FAAH levels was seen in the
mPFC of Fischer rats (values mPFC: Wistar: 0.6460.03; Fischer:
0.4960.05) (Fischer: n=6, Wistar n=6).
pERK1/2 Stimulation. Expression of pERK1/2 was
measured by Western Blot analysis, after stimulation with the
CB1 receptor agonist WIN in the HPC (Figure 7), since this was
the only brain region where different CB1 receptor protein levels
were discovered between the strains. Although the expression of
ERK1 and ERK2 was found to be similar, the signal was always
much stronger for pERK2 than for pERK1, which was below the
detection threshold in some experiments. Similar low expression of
pERK1 has been described by other studies after cannabinoid
treatment [40]. Therefore, only values of pERK2 were used for
statistical analysis. Statistical analysis revealed a significant
interaction effect (F1,20=7.01; p,0.05) for the factors strain and
treatment. Post-hoc analysis indicated that acute WIN
administration significantly increased pERK2 expression in
Wistar rats compared to vehicle treated controls (p=0.007) but
this WIN-induced increase was absent in Fischer rats (p.0.05)
(Fischer: VEH: n=6, WIN: n=6; Wistar: VEH: n=6, WIN:
n=6).
Discussion
The aim of the present study was to examine possible
differences in reward sensitivity towards a palatable food reward
in Fischer and Wistar rats. In addition we examined if changes in
ECB signaling might be involved in strain specific differences in
reward-related behavior. We detected lower reward sensitivity in
Fischer rats towards a food reward compared to the Wistar strain,
Figure 1. SCM intake in Wistar and Fischer rats in a limited
access paradigm. Fischer rats consumed significantly less SCM than
Wistar rats. Values are expressed as means 6 SEM (p,0.05 is indicated
by asterisks).
doi:10.1371/journal.pone.0031169.g001
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alike. These distinctive behavioral alterations were paralleled by
basic changes in the ECB system, with Fischer rats expressing
lower protein levels of the CB1 receptor and FAAH, as well as a
lower ligand-induced stimulation of the CB1 receptor. Accord-
ingly, Wistar rats showed a stronger behavioral response towards
acute applications of the CB1 receptor antagonist/inverse agonist
SR and the cannabinoid agonist WIN.
Reward sensitivity
Fischer rats were found to express considerably lower reward
sensitivity towards a palatable food reward than Wistar rats. For
the assessment of reward sensitivity, consummatory, hedonic as
well as motivational aspects of a food reward (SCM) were
examined in Fischer and Wistar rats. Wistar rats consumed
significantly more SCM during a limited access paradigm than
Fischer rats. These findings are not related to a higher anxiogenic
state or novelty-induced hypophagia in Fischer rats, since all
animals were habituated repeatedly to the SCM and the complete
testing procedure. Similar results were also reported in a previous
study by Tordoff et al. [31], in which Wistar rats (vendor: Charles
River) had a higher intake (but not preference) of polycose,
saccharine and sucrose solutions (especially for lower concentra-
tions) during a 48-h test period compared to Fischer rats (vendor:
Teconic), although in this study animals were single housed and
not habituated to the liquids before testing. Notably, Fischer and
Wistar rats were found to express a similar number of fungiform
taste papillae on the tongue, indicating no differences in their
abilty to detect sweet tastants and did also not differ in their
normal food intake (g/kg body weight) [31].
Besides the effects in consummatory behavior, we also observed
strain differences in motivational behavior during PR testing.
Wistar rats performed more lever presses and reached a higher last
ratio compared to Fischer rats. Interestingly, no significant
differences were detected in the inactivity ratio (no response for
over 2 min) which was taken as a measure for the ‘break point’ in
responding. These findings are partially consistent with an earlier
study, showing that Fischer and Wistar rats did not differ
significantly in ‘‘break points’’ for food reward [13]. However,
no other parameters beside the break point (inactivity interval of
10 min) have been recorded in this specific study (e.g. total
number of lever presses), since PR sessions ended as soon as the
break point criterion was reached. We recently demonstrated that
these different variables (break point and total lever pressing or
highest completed ratio) measure different aspects during PR
Figure 2. PR testing in Wistar and Fischer rats. A significant decrease in total lever presses (A) and (B) highest completed ratio was found in rats
from the Fischer strain compared to Wistar rats. No significant strain differences were detected regarding the inactivity ratio (C). Values are expressed
as means 6 SEM (p,0.05 is indicated by asterisks).
doi:10.1371/journal.pone.0031169.g002
Figure 3. PAS in Wistar and Fischer rats. A significant lower
percentage PAS response was detected in Fischer rats compared to
Wistar rats, indicating a lower inhibitory effect of the conditioned odor
on the startle magnitude in Fischer rats. Values are expressed as means
6 SEM (p,0.05 is indicated by asterisks).
doi:10.1371/journal.pone.0031169.g003
Figure 4. Strain specific effects of the cannabinoid receptor
agonist WIN 55,212-2 (WIN) on locomotor activity. Wistar and
Fischer rats did not differ significantly in their basic locomotor activity.
However, an acute injection of WIN (2 mg/kg) had a stronger inhibitory
effect on distance traveled in Wistar than in Fischer rats. Values are
expressed as means 6 SEM (p,0.05 is indicated by asterisks).
doi:10.1371/journal.pone.0031169.g004
Rat Strain Differences in Reward Processing
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the first ‘‘break’’ in responding [29,30]. Aside from motivational
aspects, the aversiveness of the progressive increase requires lever
pressing and the frustration induced by the unexpected omission of
reward also contribute to this first break in perseveration, but do
not affect later responding. Another difference between the
Freeman study and our present experiments is the diet, for which
our animals were held ad libitum and not food restricted. A stronger
motivation to obtain food after restricted feeding might attenuate
differences in reward-related behaviors between the two strains.
We also examined possible rat strain differences in hedonic
reward processing with the PAS paradigm. The startle probe
procedure serves as a very effective means for assessing emotions,
since the ASR can be modulated in humans and rats by the
organism’s ongoing motivational state. The decrease of the ASR
amplitude, if elicited in a pleasant emotional context (e.g. the
appetitive conditioned odor), serves as a cross-species model to
measure reward related affect [28,32]. The PAS paradigm offers a
completely new approach for investigating the neural mechanisms
of reward, since it measures the reduction of an aversive reflex,
instead of reinforcing or increasing certain behaviors [28]. Fischer
rats had a significantly lower percentage PAS, compared to Wistar
rats. Although the appetitive conditioned odor-cue reduced the
aversive startle reflex in both rat strains, this inhibitory effect was
found to be much more pronounced in Wistar than Fischer
animals, and therefore indicating a stronger hedonic effect of the
odor-cue in the Wistar strain.
Alltogether, our findings indicate that Wistar rats express a
higher reward sensitivity towards a palatable food reward
compared to Fischer rats, although the response towards primary
frustrating events appears not to differ between the strains.
Molecular and pharmacological differences regarding
ECB functionality
Consistent with previous studies [33–35], CB1 receptor
antagonism significantly decreased the intake of a palatable food
reward in both rat strains, however, Fischer rats were found to be
less sensitive towards the inhibitory effects of SR on consumma-
tory behavior than the Wistar strain. In Wistar rats, the lowest
dose of SR (0.3 mg/kg) already induced a significant decrease in
SCM intake, whereas this dose had no effect in Fischer rats.
Additionally, the highest dose of SR induced stronger behavioral
effects in Wistar than in Fischer rats. The percentage inhibitory
effects of SR were therefore more distinct in Wistar than Fischer
animals.
Similar strain effects were detected for the inhibitory effects of a
high dose of WIN on locomotor activity, which were found to be
much more pronounced in Wistar rats compared to Fischer rats.
These findings are in line with our observations on significantly
lower protein expression levels of the CB1 receptor and the AEA
Figure 5. Strain specific effects of SR141716 (SR) on SCM intake. SCM intake in Wistar (A) and Fischer rats (B), as well as percentage reduction
of SCM consumption (B) in both strains (C). All three concentrations of SR significantly reduced SCM intake in Wistar rats (A) (p,0.05 is indicated by
one asterisk; p,0.001 is indicated by two asterisks). In addition, SCM intake in Wistar rats after treatment with 1.2 mg/kg SR was also significantly
reduced compared to treatment with the lowest dose (p,0.05 is indicated by one diamond). In Fischer rats only the two highest concentrations of SR
induced a significant attenuation of SCM intake compared to vehicle treatment (B) (p,0.05 is indicated by one asterisk). The percentage inhibition of
SCM intake (C) induced by SR was overall significantly stronger in the Wistar strain compared to Fischer rats. Values are expressed as means 6 SEM.
doi:10.1371/journal.pone.0031169.g005
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compared to the Wistar strain. Additionally, we observed a trend
for decreased FAAH levels in the mPFC of Fischer rats. No
significant differences were found in other brain regions examined
in the present study, such as striatum and NAC. This is the first
study demonstrating strain differences regarding CB1 receptor
expression levels. Although levels of ECB ligands such as AEA
were not examined in the present study, the fact that two
important components of the brain ECB system are expressed to a
lower extent in the HPC of Fischer rats, might indicate a basic
lower ECB tone in these animals. Both CB1 receptors and FAAH
are very abundant in the HPC [36,37], which might explain why
the strongest strain differences for CB1 receptor expression were
discovered specifically in this region. Although no differences were
observed for other reward-related brain regions (NAC, mPFC and
striatum) in CB1 receptor protein levels, it is still possible that the
functionality of the receptor or the endocannabinoid levels differ
between the rat strains, which needs to be adressed in future
studies. The strong decrease in hippocampal expression of
important components of the ECB system in Fischer rats was
paralleled by a lower cannabinoid-stimulated ERK activation in
this region. WIN-induced stimulation of the CB1 receptor was
found to activate ERK phosphorylation in the HPC to a much
stronger extent in Wistar rats compared to the Fischer strain. That
cannabinoid agonists are able to activate ERK in the HCP has
been demonstrated before in vitro as well as in vivo [38–40]. This
activation is mediated specifically by CB1 receptors since it can be
prevented by pre-treatment with SR and additionally, ERK
stimulating effects of cannabinoids are absent in CB1 receptor
knockout mice [40].
Finally, our findings on stronger acute behavioral inhibition of
SCM intake by SR in Wistar rats compared to Fischer rats, as well
as the stronger behavioral response towards the effects of the
cannabinoid agonist WIN, are consistent with a lower availability
Figure 6. CB1 receptor (A) and FAAH (B) protein levels in different brain regions of Wistar and Fischer rats. Lower protein levels of the
CB1 receptor (CB1-R) and FAAH were detected in the HPC of Fischer rats compared to the Wistar strain. Additionally, a trend for lower FAAH protein
levels was observed in the mPFC of Fischer rats. No differences were observed for FAAH and CB1-R in other brain regions tested. Values are expressed
as means 6 SEM (p,0.05 is indicated by asterisks; p,0.1 is indicated by #).
doi:10.1371/journal.pone.0031169.g006
Figure 7. Cannabinoid-induced ERK phosphorylation in the
HPC of Wistar and Fischer rats. Data for pERK2 were normalized to
the optical densities of total ERK2 in the same samples and are
expressed as percentage of control. Acute administration of the
cannabinoid agonist WIN 55,212-2 (WIN) significantly stimulated ERK2
phosphorylation in Wistar rats (p,0.05 is indicated by asterisks),
whereas no such stimulatory effect could be observed in the Fischer
strain. Values are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0031169.g007
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transduction pathways, as observed in the present study. Although
SR can be classified as a CB1 antagonist, it has been well
documented in various studies in vivo and in vitro that SR behaves as
an inverse agonist rather than a neutral antagonist. Thus, its
biochemical or behavioral effects generally are opposite to the
effects of cannabinoid agonists and include among others
inhibition of MAPK activity, adenylyl cyclase activity, and GTPcS
binding in selected brain regions [41,42]. It has been suggested
that SR might bind preferentially to the so-called inactive R state
of the CB1 receptor, thereby decreasing the activation of the
signaling pathway [41,43]. Therefore, the lower availability of
CB1 receptors in the Fischer strain might well explain the reduced
behavioral effects of SR in these animals, considering its inverse
cannabimimetic action at the receptor. This is further supported
by our finding on a much stronger behavioral response towards
application of a cannabinoid agonist in Wistar than Fischer rats.
Impact of strain-specific alterations in the ECB system on
behavioral findings
Since the ECB system has been shown to be linked to various
behavioral actions, especially regarding reward-related behaviors
[16,44], basic knowledge on genetic differences in the ECB system
might provide a better insight into behavioral differences between
individuals. The molecular findings of the present study reveal
lower CB1 receptor and FAAH expression levels as well as
decreased ECB signal transduction in the HPC, and to a lesser
extent in the mPFC, of Fischer rats in comparison to the Wistar
strain. Both regions, the HPC as well as the PFC, have been
implicated in reward processing [45,46]. Growing evidence
indicates an important modulatory role of the ECB system in
reward-related behavior [16,17], which has been shown to include
ECB signaling in the HPC and the PFC [47,48]. Although the
HPC is generally not considered the primary region for brain
reward processing, studies have indicated the importance of this
structure for food-related and appetitive behaviors [46,49,50]. It
has been shown that access to a highly palatable diet for some
weeks in rats leads to a considerable down-regulation of CB1
receptor expression in extrahypothalamic regions, such as the
HPC and the NAC, implying the HPC as an important brain
region for endocannabinoid signaling in the context of appetitive
food intake [46]. The modulatory influence of the HPC on reward
processing has been suggested to derive mainly through its close
anatomical connectivity with the nucleus accumbens [49,50].
Molecular differences observed between both rat strains in the
ECB system are further supported by our findings on decreased
sensitivity of Fischer rats towards cannabinoid pharmacology. It is
therefore quite conceivable that the behavioral phenotype of low
reward sensitivity observed in Fischer rats in comparison to Wistar
rats, is related to the low expression of important ECB components
and concomitant lower activation of ECB signaling pathways in
the Fischer strain.
It has been reported that genomic variations in the human CB1
receptor gene (Cnr1) appear to be involved in the vulnerability
towards substance abuse and addictive behaviors [51–54].
Furthermore, variations in the Cnr1 and FAAH genes have been
reported to be associated with a differential neural response to
marijuana cues in reward pathways [55].
Additional support for the involvement of genetic variations in
the ECB system in behavioral differences is given by various
studies using CB1 receptor knockout mice. CB1 receptor knockout
mice were found to eat less than their wild type control littermates
after food restriction [56], have lower break points under PR
schedules of sucrose delivery [57] and show decreased sucrose
preference and consummption in a free-choice procedure [57,58].
Additionally, lower intake rates and reinforcement strength of
different drugs of abuse have been reported in CB1 receptor
deficient mice compared to controls, indicating a functional role of
the ECB system in mediating the addictive properties of drugs of
abuse [19,59–61].
Notably, in our study we did not only observe a decrease in
intake and motivational properties of SCM in the Fischer strain,
but the hedonic value of this palatable liquid was also attenuated
in Fischer rats. It is well known that reward motivation and the
hedonic impact of a reward are mediated by different neurotrans-
mitter systems. The dopaminergic system appears to be crucial for
cost-benefit calculations and motivated behavior [62,63], whereas
the endogenous opioid system is suggested to mediate euphoric or
hedonic aspects of reward processing [17,64,65]. In line with these
studies it has been demonstrated that the opioid antagonist
naloxone dose-dependently decreases the PAS reponse [29], but
neither dopaminergic D1 nor D2 receptor antagonists were found
to affect PAS [32], thereby confirming the importance of the
endogenous opioid system for the evaluation of hedonic properties
of rewarding stimuli. The ECB system appears to be an important
modulator of motivational and hedonic aspects of reward
processing alike [17,24,66–68], mainly by close interactions with
the dopaminergic [69,70] and endogenous opioid system [17,71].
Hence the lower reward sensitivity for consummatory, motiva-
tional and hedonic properties of the food reward in rats from the
Fischer strain might be related primarily to our findings on
decreased ECB activity in this rat strain, although concomittant
changes in the dopaminergic or endogenous opioid system can not
be excluded.
Alltogether, data from various studies in humans and rodents
are demonstrating the important modulatory influence of (genetic)
differences in the ECB system on reward-related behavior,
indicating that reduced ECB activity is linked to attenuated
reward processing.
Conclusion
The present data demonstrate pronounced differences between
the Fischer and the Wistar strain in different aspects of reward-
related behavior. These behavioral findings are paralleled by
congential differences in the ECB system between both rat strains.
Aside from the lower reward sensitivity towards a palatable food
reward, Fischer rats were found to be less sensitive towards
cannabinoid treatment and to express lower levels of the CB1
receptor and FAAH, mainly in the HPC. These basic differences
in the ECB system between both rat strains might contribute to the
differences observed in reward sensitivity. Our data indicate that
Fischer rats, in comparison to Wistar rats, represent a rat strain
with a strong decrease in basic reward sensitivity and might
therefore serve as a suitable model to further investigate rat strain
differences in reward processing. Finally, the Fischer strain might
also be of use to study the consequences of low ECB signaling, in
comparison to other rat strains.
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